HAND2 and invasive breast carcinoma: As demonstrated in Figure 5A, HAND2-AS1 was significantly downregulated in bladder urothelial carcinoma, breast invasive carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, colon adenocarcinoma, liver hepatocellular carcinoma, rectum adenocarcinoma, and uterine corpus endometrial carcinoma when compared with control.